Investigational drug · Phase 3
Pemetrexed and Cisplatin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic NSCLC.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
663
Any phase or sponsor naming "Pemetrexed and Cisplatin"
First trial start
2026
Oct 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pemetrexed and Cisplatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "Pemetrexed and Cisplatin" as an intervention, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
Myung-Ju AhnAcademic, hospital or other
NCT04909164 · 1,519 participants · Start Jun 15, 2021 · Primary completion Dec 31, 2025
Drug: Immunnotherapy group · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Seoul, South Korea
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00324805 · 1,501 participants · Start Jul 19, 2007 · Primary completion Oct 20, 2015
Drug: Bevacizumab; Cisplatin and 4 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 and 1 more
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,169 sites in all
- De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy InductionPivotal-lookingRecruiting
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
NCT05255302 · 1,360 participants (planned) · Start May 2, 2022 · Primary completion May 2025
Drug: Pembrolizumab before randomization; Chemotherapy and 2 more · For: Metastatic NSCLC
Sites: Aix-en-Provence, France; Amiens, France; Angers, France · 44 sites in all
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05687266 · 1,350 participants · Start Dec 29, 2022 · Primary completion Nov 1, 2027
Drug: Datopotamab deruxtecan; Durvalumab and 5 more · For: NSCLC
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 254 sites in all
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02486718 · 1,280 participants · Start Oct 31, 2015 · Primary completion Jan 26, 2024
Drug: Atezolizumab; Cisplatin and 4 more · For: Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Encinitas, California; Fountain Valley, California · 216 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Malignant mesothelioma of the tunica vaginalis testis: A case report.
Lu Y, Miu J, Fan Z, et al. · Oncol Lett 2026
- Nivolumab induces seven-year sustained remission in a patient with advanced PD-L1-positive lung adenocarcinoma: a case report.
Sheng H, Zhang W, Yu Q, et al. · Front Oncol 2026
- Case Report: A patient harboring rare EGFR S768I/V769L compound mutation benefited from afatinib and osimertinib.
Cui Q, Zhao J, Ma Y, et al. · Front Pharmacol 2026
- Primary Malignant Mesothelioma of the Tunica Vaginalis Presenting as a Benign Scrotal Mass: A Case Report.
Dagdeviren ZC, Amac O, Dere Y, et al. · Cureus 2025
- Successful conversion surgery following tislelizumab with chemotherapy in a patient with stage IIIC lung adenocarcinoma harboring RET fusions: A case report and review of the literature.
Tu DH, Qu R, Wen F, et al. · Exp Ther Med 2025
- Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma.
Li X, Xu H, Hong R, et al. · Int Immunopharmacol 2025
Also in development for Advanced or Metastatic NSCLC
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- HS-10504Phase 31 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Advanced or Metastatic NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.